Novel Biomarkers for Early Detection of Renal Impairment: A Promising Outlook

Michael Frade^*
*Correspondence: Michael Frade, Department of Nephrology, University of Otago, 362 Leith Street, Dunedin North, Dunedin 9016, New Zealand, Email:

Introduction

Renal impairment is a prevalent and potentially debilitating condition affecting millions of individuals worldwide. Timely detection and intervention are crucial for preventing the progression to end-stage renal disease and improving patient outcomes. Traditional biomarkers, such as serum creatinine and estimated glomerular filtration rate, have limitations in detecting early renal dysfunction. This research article explores the promising outlook of novel biomarkers that have emerged as valuable tools for early detection of renal impairment, paving the way for enhanced clinical management and improved patient care.

Renal impairment is a global public health concern characterized by the progressive decline in kidney function. Chronic kidney disease is an umbrella term that encompasses various stages of renal impairment, and it affects an estimated 10% of the global population. CKD is associated with numerous risk factors, including hypertension, diabetes, and cardiovascular diseases [1-3]. Early detection and intervention are pivotal in preventing CKD progression to ESRD, reducing the associated economic burden, and enhancing patients' quality of life. Traditional biomarkers used to diagnose and monitor renal impairment, such as serum creatinine and eGFR, have inherent limitations. Serum creatinine is influenced by muscle mass and is insensitive to early renal dysfunction. eGFR is an estimate rather than a direct measure of kidney function. Consequently, these biomarkers may fail to detect renal impairment in its early stages, hindering timely intervention.

Description

Recent advancements in the field of nephrology have led to the identification of novel biomarkers that offer improved sensitivity, specificity, and early detection capabilities. These novel biomarkers can be broadly categorized into the following groups: Biomarkers of tubular injury, such as neutrophil gelatinase-associated lipocalin and kidney injury molecule-1, have shown promise in identifying early renal dysfunction. NGAL, in particular, has been associated with various renal insults and can be detected in urine and serum. KIM-1 is a transmembrane protein upregulated during renal injury and is considered a highly specific marker for tubular damage. Inflammation plays a crucial role in the pathogenesis of renal impairment.

Novel biomarkers like C-reactive protein, interleukin-18, and tumor necrosis factor-alphahave demonstrated potential in detecting inflammation associated with renal dysfunction. Metabolomics, the study of small molecules in biological systems, has unveiled promising biomarkers associated with early renal impairment [4,5]. Metabolites such as asymmetric dimethylarginine and trimethylamine-N-oxide have been linked to impaired renal function and have the potential to provide valuable insights into early detection.

Genetic factors contribute significantly to the risk of developing CKD. Polymorphisms in genes encoding proteins involved in renal function, such as Apolipoprotein L1 (APOL1) and UMOD, have been associated with CKD susceptibility. Genetic biomarkers can help identify individuals at higher risk of renal impairment. The utilization of these novel biomarkers in clinical practice offers several advantages. Early detection allows for prompt intervention, potentially halting or slowing the progression of CKD. These biomarkers can also aid in risk stratification, guiding treatment decisions and optimizing therapeutic strategies. Furthermore, they may facilitate the development of targeted therapies for specific renal impairment etiologies.

Conclusion

The early detection of renal impairment is critical for improving patient outcomes and reducing the burden on healthcare systems. While traditional biomarkers have limitations in detecting early renal dysfunction, the emergence of novel biomarkers offers a promising outlook. These biomarkers, spanning various categories, provide enhanced sensitivity and specificity, enabling timely intervention and improved clinical management. Continued research and validation of these novel biomarkers are essential to realizing their full potential in the early detection of renal impairment, ultimately benefitting both patients and healthcare providers.

References

1. Rayego-Mateos, Sandra and Jose M. Valdivielso. "New therapeutic targets in chronic kidney disease progression and renal fibrosis." Exp Opin Ther Targets 24 (2020): 655-670.

Google Scholar, Crossref, Indexed at

2. Mallamaci, Francesca, Anna Pisano and Giovanni Tripepi. "Physical activity in chronic kidney disease and the ExerCise Introduction to Enhance trial." Nephrol Dial Transplant 2 (2020): ii18-ii22.

Google Scholar, Crossref, Indexed at

3. Carrero, Juan J., Ailema González-Ortiz, Carla M. Avesani and Stephan JL Bakker, et al. "Plant-based diets to manage the risks and complications of chronic kidney disease." Nat Rev Nephrol 16 (2020): 525-542.

Google Scholar, Crossref, Indexed at

4. Piccoli, Giorgina Barbara, Tommy Cederholm, Carla Maria Avesani and Stephan JL Bakker, et al. "Nutritional status and the risk of malnutrition in older adults with chronic kidney disease-implications for low protein intake and nutritional care A critical review endorsed by ERN-ERA and ESPEN." Clin Nutr (2023).

Google Scholar, Crossref, Indexed at

5. Valente, Ana, Joana Jesus, Joana Breda and Ana Dinis, et al. "Dietary Advice in hemodialysis patients: Impact of a Telehealth approach during the COVID-19 pandemic." J Ren Nutr 32 (2022): 319-325.

Google Scholar, Crossref, Indexed at